🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Race for Zika vaccine gathers momentum as virus spreads

Published 01/29/2016, 07:44 PM
© Reuters. A technician of Oswaldo Cruz Foundation (Fiocruz) inspects an Aedes aegypti mosquito in Recife
INO
-

By Rod Nickel and Natalie Grover

(Reuters) - Companies and scientists are racing to create a Zika vaccine as concern grows over the mosquito-borne virus that has been linked to severe birth defects and is spreading quickly through the Americas.

Zika is now present in 23 countries and territories in the Americas. Brazil, the hardest-hit country, has reported around 3,700 cases of the devastating birth defect called microcephaly that are strongly suspected to be related to Zika.

The Geneva-based World Health Organization (WHO), stung by criticism that it reacted too slowly to West Africa's Ebola epidemic, convenes an emergency meeting on Monday to help determine its response to the spread of the virus.

The U.S. Centers for Disease Control and Prevention has activated an emergency operations center staffed around the clock to address Zika, agency officials told Reuters.

On Thursday, the WHO said as many as 4 million people in the Americas may become infected by Zika, adding urgency to the research efforts. Vaccine developers made clear a vaccine for widespread public use is at least months, if not years, away.

The closest prospect may be from a consortium including drugmaker Inovio Pharmaceuticals Inc (O:INO) that could have a vaccine ready for emergency use before year-end, according to one of its lead developers. Inovio's share price gained more than 15 percent in Friday trading.

Canadian scientist Gary Kobinger told Reuters on Thursday the first stage of testing on humans could begin as early as August. If successful, the vaccine might be used during a public health emergency by October or November, said Kobinger, who helped develop a trial vaccine for the Ebola virus.

Privately owned vaccine developer Hawaii Biotech Inc said it began a formal program to test a Zika vaccine last fall as the virus started to gain traction in Brazil, although it has no timetable yet for clinical trials.

"Right now, we are in the pre-clinical stage, as I suspect everyone is," Chief Executive Officer Dr. Elliot Parks told Reuters.

Another private vaccine developer, Boston-based Replikins Ltd, said it was preparing to start animal studies on a Zika vaccine in the next 10 days. Data from the trials on mice and rabbits would likely be out in the next couple of months, Replikins Chairman Samuel Bogoch told Reuters.

"No one has the $500 million on hand to take it (a vaccine) all the way to human trials. Somewhere along the course we hope to have big pockets join us," Bogoch said.

'FIGHT THE MOSQUITO'

Zika had been viewed as a relatively mild illness until Brazilian health officials identified it as a matter of concern for pregnant women. While a direct causal relationship has not been established, scientists strongly suspect a link between Zika and thousands of children born in Brazil with abnormally small heads, brain defects and impaired vision.

There is no treatment for Zika infection.

Efforts to combat Zika are focused on protecting people from being bitten and on eradicating mosquitoes, a tough task in many parts of Latin America, where people live in poverty and there are plentiful breeding grounds for the insect.

"We do not have a vaccine for Zika yet. The only thing we can do is fight the mosquito," Brazilian President Dilma Rousseff said on Friday, reiterating her call for a national eradication effort.

Rousseff said tests for the development of a vaccine would begin next week at the Butantan Institute, one of Brazil's leading biomedical research centers in Sao Paulo.

U.S. President Barack Obama spoke on Friday with Rousseff about the spread of the virus, the White House said.

"The leaders agreed on the importance of collaborative efforts to deepen our knowledge, advance research and accelerate work to develop better vaccines and other technologies to control the virus," the White House said in a statement.

Zika has hit Brazil just as it prepares to host the Olympic Games in Rio de Janeiro on Aug. 5-21, an event that draws hundreds of thousands of athletes, team officials and spectators. The International Olympic Committee (IOC) assured teams on Friday the Olympics would be safe from Zika, but urged visitors to carefully protect themselves.

U.S. lawmakers have begun to press the Obama administration for details of its response to Zika. At least 31 people in the country have been infected, all of them after travel to affected countries.

The U.S. Senate Health, Education, Labor and Pensions Committee is planning a hearing on Zika "very soon," said Republican Senator Lamar Alexander of Tennessee, who called the threat posed by the virus to the United States a "big concern."

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Disease, said he did not expect the United States to be hit hard like other some countries in South America and the Caribbean.

"We prepare for the possibility of a major outbreak but we believe it is unlikely to happen," Fauci said.

© Reuters. A technician of Oswaldo Cruz Foundation (Fiocruz) inspects an Aedes aegypti mosquito in Recife

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.